All In Biotech

Drug Trial Radar · NCT05501418

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19

A Seamless Phase I/IIa Clinical Study to Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Severe and Critical COVID-19 Condition

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 5, 2020

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to explore the safety and efficacy of using UCMSC01 in patients with COVID-19 infection via IV stem cell administration. The novelty of the current UMSC01 treatment is the single IV infusion of UMSC01 to the worldwide emergency outbreaks of COVID-19. We hypothesize that sufficient UMSC01 retention in lung may modulate the systemic inflammatory responses.

Conditions

  • COVID-19 Infection

Interventions

  • Allogeneic umbilical cord mesenchymal stem cellsBiological

    UMSC01 cells will be IV infusion with 12 months of follow up after treatment.

  • Controlled normal salineBiological

    Normal saline will be IV infusion with 12 months of follow up after treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Two Co-Primary Efficacy EndpointsTime frame: 21 days of the treatment period
  2. Two Co-Primary Efficacy EndpointsTime frame: 21 days of the treatment period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Medical University Hospital

    Taichung, Non-US, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.